Skip to Main Content

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Conditions

Prostate

Phase III

What is the purpose of this trial?

The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.

  • Ages
    18 years and older
  • Gender
    Male only
  • Trial with
    Endocyte, Inc.
  • Start Date
    07/21/2019
  • End Date
    08/30/2020
Trial Image

For more information about this study, contact:

Matthew Piscatelli

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/23/2019
  • Study HIC
    #2000023966